Home/ Stocks/ INKT

MiNK Therapeutics, Inc. Common Stock

INKT XNAS

$10.95 -0.05 (-0.45%) ▼ 15-min delayed

Open

$10.90

High

$11.57

Low

$10.89

Volume

4.7K

Market Cap

$54.80M

About MiNK Therapeutics, Inc. Common Stock

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 15 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$80.8K	$-2,742,368	$-0.57
FY 2025	$180.2K	$-12,494,260	$-2.93
Q3 2025	$55.2K	$-2,887,709	$-0.65
Q2 2025	$348	$-4,237,751	$-1.06

Related Market News

No specific coverage for INKT yet. Check out our latest market news or earnings calendar.

Get INKT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on MiNK Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.